Chemotherapy-induced peripheral neuropathy: Clinical features, diagnosis, prevention and treatment strategies

Clinical and Translational Oncology

Volumn 12, Issue 2, 2010, Pages 81-91

  Gutiérrez Gutiérrez, Gerardo ^a   Sereno, María ^a   Miralles, Ambrosio ^a   Casado Sáenz, Enrique ^a   Gutiérrez Rivas, Eduardo ^b  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Cancer; Chemotherapy; Neuropathy; Neuroprotection; Pain; Polyneuropathy

Indexed keywords

21 AMINOEPOTHILONE B; ALKYLATING AGENT; AM 424; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTARABINE; DIMESNA; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; ETOPOSIDE; GEMCITABINE; GLUTATHIONE; IXABEPILONE; LAMOTRIGINE; LENALIDOMIDE; NEUROPROTECTIVE AGENT; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; PROTEASOME INHIBITOR; SAGOPILONE; TAXANE DERIVATIVE; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE; VINDESINE; PLATINUM DERIVATIVE; VITAMIN;

AUTONOMIC NEUROPATHY; BLOOD TOXICITY; BREAST CANCER; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CRANIAL NEUROPATHY; DIAGNOSTIC TEST; DIPLOPIA; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MEGADOSE; DRUG WITHDRAWAL; FACE DISORDER; FACIAL NERVE PARALYSIS; FOOT DISEASE; GLIOBLASTOMA; HAND PARESTHESIA; HEMATOLOGIC MALIGNANCY; HUMAN; LARYNX DISORDER; LEG CRAMP; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MALNUTRITION; MOTOR NEUROPATHY; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; NERVE FIBER; NERVE FUNCTION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROANATOMY; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; ORAL PARESTHESIA; PARALYSIS; PARESTHESIA; PERCEPTION DEAFNESS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; QUALITY OF LIFE; QUANTITATIVE DIAGNOSIS; RECURRENT CANCER; REVIEW; SENSORY DYSFUNCTION; SENSORY NERVE; SENSORY NEUROPATHY; SOLID TUMOR; SOMNOLENCE; SYMPTOM; TERATOGENICITY; THROAT DISEASE; TREATMENT RESPONSE; ANIMAL; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; DIET SUPPLEMENTATION; EVALUATION; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIETARY SUPPLEMENTS; HUMANS; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES; PLATINUM COMPOUNDS; VITAMINS;

EID: 77951649382     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/S12094-010-0474-z     Document Type: Review

References (90)

1. Walker M, Ni O (2007) Neuroprotection during chemotherapy: a systematic review. Am J Clin Oncol 30:82-92
2. Cavaletti G, Bogliun G, Marzorati L et al (1994) Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res 14:1287-1292
3. Mileshkin L, Antil Y, Rischin D (2002) Management of complications of chemotherapy. In: Gershenson DM, McGuire MP, Gore M et al (eds) Gynaecologic cancer: controversies in management. Elsevier Science, Philadelphia, PA
4. Wolf S, Barton D, Kottschade L et al (2008) Chemotherapy- induced neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507-1515
5. Mileshkin L, Stark R, Day B et al (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507-4514
6. National Cancer Institute (NCI) (2006) Nerve changes in patients who are undergoing chemotherapy or biological therapy for cancer. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: http://clinicaltrials.gov/ct2/show/NCT00281853?term= cancer+AND+neuropathy&rank=33
7. MD Anderson Cancer (2009) Chemotherapyinduced peripheral neuropathy survey. In: ClinicalTrials. gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: http://clinicaltrials.gov/ct2/show/ NCT01016028?term=cancer+AND+neuropathy&rank=14
8. Gardner ED, Bunge RP (2005) Gross anatomy of the peripheral nervous system. In: Dyck PJ, Thomas PK (eds) Peripheral neuropathy, 4th edn. Elsevier, Philadelphia, pp 11-34
9. Berthold SH, Fraher JP, King RHM et al (2005) Microscopic anatomy of the peripheral nervous system. In: Dyck PJ, Thomas PK (eds) Peripheral neuropathy, 4th edn. Elsevier, Philadelphia, pp 35-91
10. Cecilia Conde C, Cáceres A (2009) Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 10:319-332
11. Hughes R (2008) Peripheral nerve diseases. Pract Neurol 8:396-405
12. Serra Catafau J (2006) Concepto de dolor neuropático. In: Serra Catafau J (ed.) Dolor neuropático. Médica Panamericana, Madrid, pp 17-26
13. Devigili G, Tugnoli V, Penza P et al (2008) The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 131:1912-1925
14. Hughes R (2008) Peripheral nerve diseases. Pract Neurol 8:396-405
15. Pestronk A, Florence J, Levine T et al (2004) Sensory exam with a quantitative tuning fork. Rapid, sensitive and predictive of SNAP amplitude. Neurology 62:461-464 (Pubitemid 38200861)
16. Martina IS, van Koningsveld R, Schmitz PI et al (1998) For the European Inflammatory Neuropathy Cause and Treatment (INCAT) group. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry 65:743-747
17. Botez SA, Liu G, Logigian E et al (2009) Is the bedside timed vibration test reliable? Muscle Nerve 39:221-223
18. Zara G, Ermani M, Rondinone R et al (2008) Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry 79:1258-1261
19. Postma TJ, Heimans JJ (2000) Grading of chemotherapy- induced peripheral neuropathy. Ann Oncol 11:509-513
20. Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advance colorectal cancer: a randomized, double-blind, placebo- controlled trial. J Clin Oncol 20:3478-3483
21. Park SB, Lin CS-Y, Krishnan AV et al (2009) Oxaliplatin- induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132:2712-2723
22. Mileshkin L, Stark R, Day B et al (2006) Aparición de neuropatía en los pacientes con mieloma tratados con talidomida: patrones de aparición y utilidad de la monitorización electrofisiológica. J Clin Oncol 24:4507-4514
23. American Association of Electrodiagnostic Medicine (2004) Technology literature review: quantitative sensory testing. Muscle Nerve 29:734-747
24. Park SB, Goldstein D, Lin CS-Y et al (2009) Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 27:1243-1249
25. Park SB, Krishnan AV, Lin CS-Y et al (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081-3094
26. England JD, Gronseth GS, Franklin G et al (2009) Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve 39:106-115
27. Sommer C (2008) Skin biopsy as a diagnostic tool. Curr Opin Neurol 21:563-568
28. Lauria G, Devigili G (2007) Skin biopsy as a diagnostic tool in peripheral neuropathy. Nat Clin Pract Neurol 3:546-557 (Pubitemid 47528029)
29. Lauria G, Lombardi R (2007) Skin biopsy: a new tool for diagnosing peripheral neuropathy. BMJ 334:1159-1162 (Pubitemid 46910023)
30. Erasmus Medical Center (2010) Skin biopsies in chemotherapy-induced neuropathy. In: Clinical- Trials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: http://clinicaltrials.gov/ ct2/show?term=cancer+AND+neuropathy&rank=34
31. Ruzzo A, Graziano F, Loupakis F et al (2007) Perfil farmacogené tico en los pacientes con cancer colorrectalavanzado tratados con quimioterapia FOLFOX-4 de primera línea. J Clin Oncol 25:1247-1254
32. Samsung Medical Center (2009) Pharmacogenomic study to predict neurotoxicity of oxaliplatin. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091220. Available from: http://clinicaltrials.gov/ct2/show/NCT00977717?term= neuropathy+and+chemotherapy&rank=32
33. Wolf S, Barton D, Kottschade L et al (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507-1515
34. Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633-1642
35. Camps C, Felip E, Sanchez JM et al (2005) Phase II trial of the novel taxane BMS-184476 as second- line in non-small-cell lung cancer. Ann Oncol 16:597-601
36. Whitehead RP, McCoy S, Rivkin SE et al (2006) A Phase II trial of epothilone B analogue BMS- 247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 24:515-520
37. McKeage MJ, Hsu T, Screnci D et al (2001) Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 85:1219-1225
38. Ta LE, Low PA, Windebank AJ (2009) Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 26:5-9
39. Gill JS, Windebank AJ (1998) Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101:2842-2850
40. Cubillo S, Cabello A, Trueba JL et al (1980) Cisplatinum neuropathy. Neurosci Lett 4[Suppl]:447
41. McKeage K (2007) Treatment options for the management of diabetic painful neuropathy: best current evidence. Curr Opin Neurol 20:553-557
42. Hansen MB (2003) The enteric nervous system III: a target for pharmacological treatment. Pharmacol Toxicol 93:1-13
43. Krishnan AV, Kiernan MC (2006) Axonal function and activity-dependent excitability changes in myotonic dystrophy. Muscle Nerve 33:627-636
44. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228-244
45. Gutiérrez-Rivas E, Alonso-Ortiz A, Téllez I et al (1984) Vindesine-induced neuropathy. Neurosci Lett 18[Suppl]:404
46. Pan YA, Misgeld T, Lichtman JW et al (2003) Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by timelapse imaging in vivo. J Neurosci 23:11479-11488
47. Kalcioglu MT, Kuku I, Kaya E et al (2003) Bilateral hearing loss during vincristine therapy: a case report. J Chemother 15:290-292
48. Verstappen CC, Koeppen S, Heimans JJ et al (2005) Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64:1076-1077
49. Ramchandren S, Leonard M, Mody RJ et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 14:184-189
50. Cavaletti G, Nobile-Orazio E (2007) Bortezomibinduced peripheral neurotoxicity: still far from a painless gain. Haematologica 92:1308-1310
51. Moehler TM, Hillengass J, Glasmacher A et al (2006) Thalidomide in multiple myeloma. Curr Pharm Biotechnol 7:431-440
52. Rabasa M, Gutiérrez-Rivas E, Díaz J et al (1994) Neuropatía tóxica por Talidomida. Neurología 9:477
53. Kotla V, Goel S, Nischal S et al (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36
54. Openshaw H, Slatkin NE, Stein AS et al (1996) Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 78:1899-1905
55. Alonso-Ortiz A, Gutiérrez-Rivas E, Cabello A et al (1990) Toxic neuropathy induced by Ara-C. J Neurol Sci 98:265
56. Thant M, Hawley RJ, Smith MT et al (1982) Possible enhancement of vincristine neuropathy by VP-16. Cancer 1:859-864
57. Dormann AJ, Grunewald T, Wigginghaus B et al (1998) Gemcitabine- associated autonomic neuropathy. Lancet 351:644
58. Sherman JE, Aregawi MD, Lai A, Fathallah- Shaykh M (2009) Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 73:1924-1926
59. Burnett AK, Kell J (2007) Tipifarnib in acute myeloid leukemia. Drugs Today (Barc) 43:795-800
60. Kovacs MJ, Reece DE, Marcellus D et al (2006) A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma: NCIC CTG IND.145. Invest New Drugs 24:529-535
61. Gutiérrez-Rivas E, Alonso-Ortiz A, Cabello A et al (1984) Toxic neuropathy due to prospidium. Neurosci Lett 18[Suppl]:403
62. Esteban PM, Thahn TG, Bravo JF et al (2009) Malnutrition associated with increased risk of peripheral neuropathy in Peruvian children with HIV infection. J Acquir Immune Defic Syndr 52:656-658
63. Gomber S, Dewan P, Chhonker D (2009) Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr (published online)
64. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
65. de Gramont A, Cervantes A, Andre T et al (2004) OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. J Clin Oncol 22:3525
66. Ghirardi O, Lo Giudice P, Pisano C et al (2005) Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 25:2681-2687
67. Bianchi G, Vitali G, Caraceni A et al (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746-1750
68. Daikhin Y, Yudkoff M (2000) Compartmentation of brain glutamate metabolism in neurons and glia. J Nutr 130:1026S-1031S
69. Gedlicka C, Kornek GV, Schmid K et al (2003) Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol 14:339-340
70. Leonetti C, Biroccio A, Gabellini C et al (2003) Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int J Cancer 104:243-250
71. Argyriou AA, Chroni E, Koutras A et al (2006) A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 14:1134-1140
72. Ferreira PR, Fleck JF, Diehl A et al (2004) Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double- blind randomized trial. Head Neck 26:313-321
73. MD Anderson Cancer Center (2005) Alpha-lipoic acid in preventing peripheral neuropathy in patients receiving chemotherapy for cancer. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: http://clinicaltrials.gov/ct2/show/NCT00112996? term=neuropathy+and+chemotherapy&rank=22
74. So YT, Simon RP (2007) Deficiency diseases of the nervous system. In: Bradley WG, Daroff RB, Fenichel GM et al (eds) Neurology in clinical practice, 5th edn. Butterworth-Heinemann, Philadelphia, pp 1643-1656
75. Ang CD, Alviar MJM, Dans AL et al (2008) Vitamina B para el tratamiento de la neuropatía periférica (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, Número 4. Update Software Ltd., Oxford. Available from: http://www.update-software.com (Traducida de The Cochrane Library, 2008 Issue 3. John Wiley & Sons, Ltd., Chichester, UK)
76. New Mexico Cancer Care Alliance (2008) A randomized phase III study of vitamins B6 and B12 to prevent chemotherapy-induced neuropathy in cancer patients. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091222. Available from: http://clinicaltrials.gov/ct2/show/ NCT00659269?term=neuropathy+and+chemotherapy&rank=3
77. Ramchandren S, Leonard M, Mody RJ et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. J Periph Nerv Syst 14:184-189
78. Kore DH, Donnelly J, McGuire WP et al (2003) Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel- induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 21:4207-4213
79. Argyriou AA, Chroni E, Polychronopoulos P et al (2006) Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67:2253-2255
80. Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-4061
81. Saif MW, Reardon J (2005) Management of oxaliplatin- induced peripheral neuropathy. Ther Clin Risk Manag 1:249-258
82. Hamers FP, Brakkee JH, Cavalletti E et al (1993) Reduced glutathione protects against cisplatininduced neurotoxicity in rats. Cancer Res 53:544-549
83. Cassidy J, Bjarnason G, Hickish T et al (2006) Randomized double blind placebo controlled phase III study assessing the efficacy of xaliproden in reducing the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5FU/ LV combination in firstline treatment of patients with metastatic colorectal cancer. J Clin Oncol 24:3507. Abstr 229
84. Traa BS, Mulholland JD, Kadam SD et al (2008) Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia. Pediatr Res 64:81-85
85. Cassidy J, Paul J, Soukop M et al (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharamacol 41:161-166
86. Hilton DJ (1992) LIF: lots of interesting functions. Trends Biochem Sci 17:72-76
87. Mamiya N, Kono T, Mamiya K et al (2007) A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer. Gan To Kagaku Ryoho 34:1295-1297
88. Shindo Y, Tenma K, Imano H et al (2008) Reduction of oxaliplatin-related neurotoxicity. Gan To Kagaku Ryoho 35:863-865
89. van der Hoop RG, VetchGJ, van der Burg ME et al (1990) Prevention of cisplatin neurotoxicity with ovarian cancer. N Engl J Med 322:89-94
90. Jackson JH (1932) Evolution and dissolution of the nervous system (Croonian Lecture). Selected writings of John Hughlings Jackson, vol.2. Hodder and Stoughton, London